NVO
Time to buy NVO?$45.64
+$0.13 (0.29%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
NVO bounced from roughly $40 in late April to about $46 by late May after Novo raised 2026 guidance and said Wegovy pill adoption was running ahead of plan.
The stock has the potential to go down if it loses $44, with a retrace toward the $40 to $41 zone possible. Any slowdown in obesity drug growth, tougher pricing pressure, or a weak update at the next earnings report would accelerate the downside.
If NVO holds the $44 to $45 area, a move back toward $50 is on the table. Resistance at $46.30 is the first hurdle, and strong volume around Wegovy pill growth or more favorable compounding rules would help.
Analyst Ratings
Novo Nordisk A/S Earnings
We don't currently have information about Novo Nordisk A/S's earnings.